Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information

NCT01445600 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01445600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01445600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Efficacy of ALTARGO(Retapamulin) Administered in Korean Patients According to the Prescribing Information
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
November 30, 2012
Completion date
August 31, 2015
Enrollment
3,612 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

skin infections, bacterial